160 related articles for article (PubMed ID: 35402236)
1. Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.
Li YZ; Chen B; Lin XY; Zhang GC; Lai JG; Li C; Lin JL; Guo LP; Xiao WK; Mok H; Ren CY; Wen LZ; Cao FR; Lin X; Qi XF; Liu Y; Liao N
Front Oncol; 2022; 12():830124. PubMed ID: 35402236
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
3. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
[TBL] [Abstract][Full Text] [Related]
4. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
5. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N
Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients.
Medić-Milijić N; Jovanić I; Nedeljković M; Marković I; Spurnić I; Milovanović Z; Ademović N; Tomić T; Tanić N; Tanić N
Life (Basel); 2024 May; 14(6):. PubMed ID: 38929666
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.
Haruna M; Daramola AO; Awolola NA; Badr NM; Banjo AAF; Shaaban A
Ecancermedicalscience; 2022; 16():1452. PubMed ID: 36405944
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract][Full Text] [Related]
9. Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression.
Sun WY; Lee J; Kim BK; Kim JO; Park J
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33804295
[TBL] [Abstract][Full Text] [Related]
10. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
11. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
12. The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Meng Y; Wu H; Yao Y; Li R
Gland Surg; 2020 Dec; 9(6):2106-2115. PubMed ID: 33447561
[TBL] [Abstract][Full Text] [Related]
13. The mutation and low expression of ARID1A are predictive of a poor prognosis and high immune infiltration in triple-negative breast cancer.
Wang Y; Chen Z; Wu J; Yan H; Wang Y; He J
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37221684
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
Huang X; Wang X; Qian H; Jin X; Jiang G
Evid Based Complement Alternat Med; 2021; 2021():5314016. PubMed ID: 34721634
[TBL] [Abstract][Full Text] [Related]
15. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
16. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
17. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
18. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
